PurpleDaisy Logo
PurpleDaisyResources
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog
Download on the App Store
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog

Biomarker Encyclopedia

500+ Items
Master Catalogs
  • All 500+ Biomarkers Directory
  • Longevity Reference MatrixPDF
Categories (500+ Markers)
  • Cardiovascular & Lipidology
  • Metabolic & Glycemic Control
  • Renal Physiology & Electrolytes
  • Hepatic & Biliary Function
  • Hematology & CBC
  • Iron Metabolism & Oxygen Transport
  • Endocrinology & Hormones
  • Micronutrients & Vitamins
  • Immunology & Longevity Clocks
Download Meridian on the App Store
Home/Biomarkers/Metabolic & Glycemic Control/FBG
Metabolic & Glycemic ControlEndocrine Pancreas & Carbohydrate Dynamics

Fasting Blood Glucose (FBG)

Fasting blood glucose measures the basal concentration of circulating D-glucose following an 8 to 12 hour overnight fast, reflecting hepatic gluconeogenesis and baseline beta-cell insulin secretion.

Standard Range70 - 99 mg/dL
Optimal Longevity75 - 85 mg/dL
Measurement Unitmg/dL
Organ SystemEndocrine Pancreas & Carbohydrate Dynamics
Routine Panels:Basic Metabolic Panel (BMP)Comprehensive Metabolic Panel (CMP)Routine Wellness

Standard vs. Optimal Reference Rangesmg/dL

Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.

Interactive Range Analyzer
Unit: mg/dL
mg/dL
Presets:
49 mg/dLOptimal Zone Target134 mg/dL
Optimal Longevity Zone(80 mg/dL)

Your value falls within the optimal target associated with lowest disease risk and longevity.

Standard Reference Interval

70 - 99 mg/dL

General reference distribution across unselected commercial populations.

Optimal Longevity Target

75 - 85 mg/dL

Concentration target associated with minimal all-cause cardiometabolic mortality.

Molecular Mechanism & Clinical Purpose

In the fasting state, basal insulin suppresses glycogenolysis and phosphoenolpyruvate carboxykinase (PEPCK)-mediated gluconeogenesis in hepatocytes. Hepatic insulin resistance leads to uninhibited glucose output despite normo- or hyperinsulinemia.

Differential Diagnosis

Elevated Levels (FBG High)

  • •Type 2 Diabetes Mellitus (>= 126 mg/dL)
  • •Impaired Fasting Glucose / Prediabetes (100 - 125 mg/dL)
  • •Cushing syndrome / Glucocorticoid excess
  • •Acute physiological stress or sympathetic activation

Low Levels (FBG Low)

  • •Insulinoma / Exogenous insulin administration
  • •Addison disease (adrenal insufficiency)
  • •Severe hepatic failure
  • •Prolonged therapeutic fasting

Technical Reference & Deep Dive

Biochemistry & Enzymatic Pathways
The physiological homeostasis of Fasting Blood Glucose (FBG) is governed by pancreatic islet beta-cell secretion, hepatic gluconeogenesis, skeletal muscle GLUT4 glucose transporter translocation, and peripheral insulin sensitivity. Cellular signal transduction occurs via the insulin receptor tyrosine kinase (IRTK), triggering phosphorylation of IRS-1 and IRS-2, which activates the phosphatidylinositol 3-kinase (PI3K)-Akt cascade and downregulates FOXO1 transcription factors. Impaired signaling causes systemic hyperinsulinemia, attenuated mitochondrial beta-oxidation, and accelerated hepatic de novo lipogenesis (DNL).
Longevity Risk Architecture & Epidemiology
Fasting glucose drifting into the upper normal quartile (86-99 mg/dL) is associated with an incremental risk of future type 2 diabetes and advanced glycation end-product (AGE) tissue cross-linking.
Pre-Analytical Caveats & Diagnostic Workup

Pre-Analytical Considerations:

Strict 10 to 12 hour overnight water-only fasting is mandatory for baseline metabolic quantification. Acute psychological stress, acute infectious illness, and sleep deprivation (<6 hours) transiently elevate cortisol and catecholamines, falsely elevating glycemic markers. For glucose and insulin testing, draw blood into sodium fluoride/potassium oxalate tubes or separate serum promptly within 30 minutes to prevent ongoing in vitro red blood cell glycolysis.

Reflexive Testing Protocol:

  • Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and HOMA-Beta calculations
  • Continuous Glucose Monitoring (CGM) 14-day wear to evaluate glycemic variability and postprandial excursions
  • Fasting C-Peptide and high-sensitivity Troponin/hs-CRP to differentiate insulin resistance from beta-cell exhaustion
  • Oral Glucose Tolerance Test (OGTT) with simultaneous 0, 30, 60, and 120-minute insulin assays
  • Abdominal ultrasound or FibroScan to evaluate hepatic steatosis and non-alcoholic fatty liver disease (MASLD)
Clinical Citations & Primary Literature (1)
  • [1]Fasting Blood Glucose and Risk of Cardiovascular Disease in Non-Diabetic Adults - Lancet Diabetes & Endocrinology (2020). PMID: 31926941
Common Panels:Basic Metabolic Panel (BMP)Comprehensive Metabolic Panel (CMP)Routine Wellness
View All Panels

Associated Longevity Guides & Clinical Calculators

Medicine 3.0

Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Fasting Blood Glucose (FBG) into overall healthspan optimization.

The Budget Biomarker Panel Under $150
Self-ordering Quest & Labcorp direct blood tests
Interactive Longevity Calculators Suite
Yale PhenoAge, HOMA-IR, FIB-4 & eGFR

Related Metabolic & Glycemic Control Biomarkers

Hemoglobin A1c
HbA1c · 4.8% - 5.2%
Fasting Serum Insulin
Fasting Insulin · 2.0 - 5.0 μIU/mL
Homeostatic Model Assessment of Insulin Resistance
HOMA-IR · < 1.0
C-Peptide (Connecting Peptide)
C-Peptide · 1.0 - 2.0 ng/mL
PreviousHigh-Sensitivity Cardiac Troponin T (hs-cTnT)Cardiovascular & LipidologyNextHemoglobin A1c (HbA1c)Metabolic & Glycemic Control